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The role of the adipocyte hormone adiponectin in
cardiovascular disease
Christopher Hug1,2,3 and Harvey F Lodish1,4Adiponectin, a novel hormone made by fat tissue, regulates
energy metabolism and endothelial activation. Serum levels of
adiponectin are reduced in conditions that are associated
with an increased risk of cardiovascular disease, such as
diabetes and the metabolic syndrome. Adiponectin trimers
assemble into higher-order oligomers, which have different
signaling properties. Adiponectin trimers and a C-terminal
globular domain activate AMP-activated protein kinase,
whereas hexamer and high-molecular weight isoforms activate
nuclear factor-kB signaling pathways. Exogenous adiponectin
corrects metabolic defects that are associated with insulin
resistance, and might protect the endothelium from the
progression of cardiovascular disease. Receptors for
adiponectin have been described and might provide future
therapeutic targets for the treatment of cardiovascular disease.
Addresses
1 Whitehead Institute for Biomedical Research, Cambridge, MA 02142,
USA
2 Division of Respiratory Disease, Children’s Hospital, Boston, MA
02115, USA
3 Harvard Medical School, Boston, MA 02115, USA
4 Department of Biology, Massachusetts Institute of Technology,
Cambridge, MA 02142, USA
Corresponding author: Lodish, Harvey F (lodish@wi.mit.edu)Current Opinion in Pharmacology 2005, 5:129–134
This review comes from a themed issue on
Cardiovascular and renal
Edited by Robert Scarborough and George Vlasuk
1471-4892/$ – see front matter
# 2005 Elsevier Ltd. All rights reserved.
DOI 10.1016/j.coph.2005.01.001
Introduction
Adiponectin, first described as Acrp30 (adipocyte com-
plement related protein of 30 kDa; [1]) and also termed
AdipoQ, Apm1 and GBP-28, is an adipokine that is
secreted specifically from differentiated adipocytes. Adi-
ponectin expression is upregulated during the differen-
tiation of preadipocytes into mature adipocytes [1]. The
primary sequence (Figure 1) of the polypeptide contains a
signal sequence (cleaved in the mature protein) and a
non-conserved N-terminal domain, followed by 22 col-
lagen repeats and a C-terminal globular domain that has
structural similarities to tumor necrosis factor a (TNF-a)
[2]. Adiponectin is abundant in serum, and is found atwww.sciencedirect.comconcentrations of up to 10 mg/ml. Like all collagen-
domain-containing proteins, the polypeptide forms the
basic unit of a trimer. The trimer self-associates through a
conserved N-terminal cysteine residue to form disulfide-
linked dimers of trimers (also termed hexamers), which
further assemble into high-molecular weight (HMW)
forms that consist of multiple oligomers of the basic
trimer. These species have been fractionated and visua-
lized using electron microscopy, as shown in Figure 2 [3].
A mutant lacking the N-terminal cysteine residue will
only form trimers [3]. A proteolytic form of the globular
C-terminal domain, although postulated to exist in vivo
[4,5], has only been studied with recombinant material.
Obese mice injected with globular adiponectin demon-
strate increased b-oxidation of fatty acids and weight loss
[4].
Adiponectin, an abundant serum adipokine, is increas-
ingly recognized to be both a potential biomarker for the
metabolic syndrome and a possible therapeutic target for
the treatment of cardiovascular disease. We will review
the recently described association of adiponectin with
cardiovascular and metabolic disease, the known activ-
ities of adiponectin as determined using in vivo and in
vitro models, and conclude with the recent description of
several adiponectin receptors.
Clinical correlations of reduced adiponectin
levels
Adiponectin is reduced in the serum of both type 2
diabetic and obese individuals, and is further decreased
in patients with cardiovascular disease [6,7]. Correction of
body weight in multiple studies, as well as improvement
of glycemic control with diet, weight loss and hypogly-
caemic agents, has resulted in normalization of adiponec-
tin levels, suggesting an intimate connection between
this adipokine and metabolic control. The ratio of HMW
to low molecular weight forms is increased following
treatment with drugs of the thiazolidinedione class of
antidiabetic agents [8,9], indicating that the complex
distribution of adiponectin isoforms has functional rele-
vance, as discussed below.
The metabolic syndrome, also termed the ‘deadly quar-
tet’ by Kaplan [10,11], consists of abdominal obesity,
insulin resistance, dyslipidemia and hypertension. Pro-
gression and development of the metabolic syndrome has
been linked to polymorphisms at the genomic locus of
adiponectin, suggesting that altered expression or activity
of adiponectin is causative in the development of this
syndrome [12]. The hypothesis that adiponectin is relatedCurrent Opinion in Pharmacology 2005, 5:129–134
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Schematic of the primary sequence of adiponectin, with amino acid
residues numbered above and domain regions indicated below. The
signal sequence (SS) is cleaved during secretion from the adipocyte,
and is followed by the non-homologous variable region (VR), which
contains the N-terminal cysteine residue 22 that is responsible for
higher-order oligomerization (see text for details). 22 collagen repeats
precede the globular domain. Trypsin cleaves adiponectin at residue
104 to generate the globular domain preparation used in initial in vivo
studies [4].to development of the metabolic syndrome was first put
forth by Matsuzawa and co-workers [13]. Several of the
individual aspects of this syndrome have been described
in association with reduced levels of adiponectin [6,7,13].
Recently, an adiponectin haplotype in the coding
sequence (designated I164T) has been described [14].
The salient points of this work are that this mutation is
associated with decreasing serum adiponectin levels to
approximately half that of the wild-type, and that these
individuals had an increase in risk factors for the meta-
bolic syndrome and cardiovascular disease relative to
control individuals lacking this mutation. Interestingly,
serum adiponectin levels associated with this haplotype
were found to be independent of the body mass index,
whereas control subjects in this study replicated the
inverse association of body mass index and adiponectin
levels described by other investigators. Other researchers
have also detected association of adiponectin haplotypes
with coronary artery disease and diabetes [15]. A large
study that examined adiponectin levels at baseline in
males free from diagnosed coronary artery disease and
that followed these subjects for six years has demon-
strated that individuals with adiponectin concentrations
in the highest quintile compared with the lowest quintile
had a decreased risk for myocardial infarction, suggestingFigure 2
Recombinant adiponectin purified from 293T cells was fractionated into each
by freeze-etch rotary shadowing. Shown are the trimer (left panel), hexamer
Experimental details are as described in [3].
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[16].
Several conditions are associated with elevated adiponec-
tin levels, and might indicate further the role of adipo-
kines in metabolic and inflammatory processes. Patients
with chronic renal failure have increased markers for
inflammation, including elevated C-reactive protein
and markers for endothelial activation. These patients
also have elevated adiponectin levels, all the more nota-
ble given the concordance of diabetes and renal failure
[17]. This is thought to represent a compensatory pro-
tective increase in adiponectin levels, although it is not
known whether the mechanism by which this occurs
involves increased adiponectin synthesis or reduced
clearance [18].
A mouse model in which the collagen domain of adipo-
nectin is truncated and overexpressed in vivo under the
control of an adipocyte-specific promoter has led, in one
founder line, to an approximately threefold increase in
serum levels of adiponectin, as well as abnormal fat
distribution including proptosis and increased interscap-
ular fat pads in female but not in male mice [19]. The
female mice were insulin sensitive and displayed lower
than normal serum triglycerides and free fatty acids,
compared to male mice. Hinting at an association with
thyroid homeostasis, the proptosis in these animals is
reminiscent of the clinical features of patients with
Graves disease; such patients have elevated adiponectin
levels and increased orbital adipogenesis [20,21].
In vitro activities of adiponectin
The in vitro biochemical activities of adiponectin depend
upon the structure and the oligomeric state of the hor-
mone, and also might be influenced by the method of
production and purification of adiponectin. Fruebis et al.
[4] used unfractionated bacterial-expressed full-length
and globular domain (produced by cleavage at residue
104 by trypsin) adiponectin to demonstrate an increased
b-oxidation of fatty acids in differentiated myotubes, an
effect that was greatest with the globular domain. Usingof the three oligomeric species and visualized in the electron microscope
(middle panel) and HMW (right panel) oligomers. Bar, 14.2 nm.
www.sciencedirect.com
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ponectin, and eukaryotic-expressed full-length adiponec-
tin, Tsao et al. [22] demonstrated that different molecular
weight pools were present, corresponding to the trimer
and hexamer species observed in serum. Notably, how-
ever, only eukaryotic-derived material was capable of
forming the HMW species found in native mouse serum;
bacterial-derived adiponectin only formed the trimeric
and hexameric species. One explanation for this result
is that the collagen domain does not fold properly in
prokaryotic-expressed proteins; alternatively, other
post-translational modifications, such as glycosylation,
might be required for proper structure formation and
oligomerization [23,24,25].
The cellular activation of adiponectin signaling pathways
has been explored by adding purified and size-
fractionated recombinant adiponectin to tissue culture
cells [22]. Using a series of reporter constructs, in which
transcriptional control elements direct the expression of
luciferase, we determined that both the hexamer and the
HMW adiponectin species activated nuclear factor (NF)-
kB-mediated gene expression driven from the E-selectin
promoter. This effect was seen using both bacterial- and
eukaryotic-derived adiponectin. In this assay, bacterial-
expressed globular and trimer preparations derived from
both eukaryotic and bacterial sources were inactive.
Other researchers have demonstrated that adiponectin
modulates the NF-kB signaling pathway, albeit using
different methods and obtaining different magnitudes
of response. By pre-treatment of tissue culture cells with
adiponectin followed by stimulation with TNF-a, Mat-
suzawa and co-workers [26] demonstrated that bacterial-
derived adiponectin inhibited subsequent NF-kB activa-
tion. The discordance of these results might, in part, be
explained by the differences in cells and experimental
techniques. Other activities of the HMW isoforms
include inhibition of endothelial apoptosis [27]; however,
the bacterial-derived preparations used in these experi-
ments might not contain native HMW forms.
A major signaling pathway that is activated by full-length
trimeric adiponectin as well as by the isolated globular
domain is that of the AMP-activated protein kinase
(AMPK) [3,28,29]. This enzyme is activated in response
to many types of cellular stress, in particular to elevated
ratios of AMP to ATP, such as those that occur during
muscle contraction and increased metabolic demand
(reviewed in [30–32]). Activation of AMPK leads to
alterations in downstream pathways that are involved
in metabolism and energy utilization, with increased
activation of ATP-generating pathways and the conco-
mitant inhibition of ATP-consuming pathways. Multiple
downstream pathways are activated; however, only two
have been well characterized in the context of cardiovas-
cular disease. These are the increase in mitochondrial
b-oxidation, which is regulated by the phosphorylationwww.sciencedirect.comand inactivation of acetyl CoA carboxylase, and the
phosphorylation and activation of malonyl CoA decarbox-
ylase, which results in the reduction of malonyl CoA
levels. The end result is an increase in the b-oxidation
of fatty acids leading to the replenishment of ATP levels.
The finding that metformin, an anti-hypoglycemic agent,
acts through this enzyme system suggests that AMPK
is intimately related to diabetes and the metabolic
syndrome [33].
In vivo activities of adiponectin
However, the association of endothelial dysfunction with
the metabolic syndrome, as well as with low levels of
adiponectin [34], raises the possibility that adiponectin
could have either direct or indirect actions on the vascular
endothelium, and that these actions might be mediated
by AMPK or NF-kB signaling. Quon and co-workers have
shown that both insulin [35] and adiponectin [36] sti-
mulate nitric oxide production in aortic endothelial cells.
This effect is hypothesized to lead to vasodilatation,
increased blood flow and increased glucose disposal.
The effects of adiponectin are blocked by inhibition of
phosphoinositide 3-kinase and by a dominant-negative
AMPK mutant [36], implying that adiponectin might
synergize with insulin in the endothelium as it does in the
liver [37].
The disruption of the gene for adiponectin has yielded
slightly varying results, with similar phenotypes being
seen by two groups. A third group [38] found that a
deletion of the adiponectin gene increased b-oxidation
but had no other metabolic effects. Kubota et al. [39]
observed moderate insulin resistance in mice that were
heterozygous for the adiponectin gene; this effect was
more severe in mice lacking both copies of the gene.
These two types of mice had similar body weights to wild-
type mice. When the femoral artery in homozygous mice
was injured with a balloon cuff, there was a twofold
increase in neointimal thickening. This result suggests
a role for adiponectin in maintaining the integrity of the
vessel wall [40].
A similar mouse strain was generated by Maeda et al. [41].
In this study, homozygous adiponectin-deficient mice
were not hyperglycemic when maintained on a normal
diet; however, they did have reduced clearance of serum
free fatty acids, and when supported on a high-fat, high-
sucrose diet they exhibited severe insulin resistance and
increased weight gain relative to control animals. TNF-a
was increased in serum and in adipose tissue of the
homozygous mice at baseline, and there was reduced
skeletal muscle expression of fatty acid transport pro-
tein-1 (FATP-1), a transmembrane protein involved in
the cellular uptake of serum fatty acids [42,43]. These
biochemical alterations, as well as the abnormal neointi-
mal proliferation following vascular injury, were corrected
by infecting the mice with an adenoviral vector expres-Current Opinion in Pharmacology 2005, 5:129–134
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tin and TNF-a act in counter-regulatory pathways and
that the net balance of their actions results in the proper
homeostasis of glucose and fatty acid metabolism. Under
conditions of metabolic stress, such as diet-induced obe-
sity in adiponectin-deficient mice, unopposed TNF-a
activity might lead to a shift towards insulin resistance.
Recently, Wong et al. have described paralogs of adipo-
nectin that might function in metabolic regulation, and
might partially compensate for the loss of adiponectin in
the knockout mice [45].
Receptors and binding proteins for
adiponectin
Receptors for many of the adipokines are well character-
ized, yet identifying the adiponectin receptor has proven
elusive. Binding of adiponectin to collagens has been
described in vitro [46]; binding to endothelial cells was
first described by Ouchi et al. [26]. Several confounding
factors influence studies of full-length adiponectin.
For example, the collagen domain undergoes prolyl-
hydroxylation, common among this protein structure.
This reaction, important in maintaining the integrity
of collagen fibrils and possibly affecting the tertiary
structure of collagen domains, does not occur in bacteria,
the source of the recombinant adiponectin used in many
studies. Mutation of conserved lysine residues that
undergo glycosylation reduces the ability of adiponectin
to inhibit hepatic glucose production [24], consistent
with the inability of bacterial-produced full-length pro-
tein to inhibit glucose secretion in isolated hepatocytes,
an activity that was seen for the full-length eukaryotic-
produced protein [37].
The situation with the globular domain of the protein is
different; no post-translational modifications have been
described and several groups have demonstrated the
activation of AMPK [28,29]. Recently, putative receptors
termed AdipoR1 and AdipoR2 have been described [47].
These proteins, distantly related to the seven-transmem-
brane spanning receptor family, were expression-cloned
using FACS enrichment of Ba/F3 cells infected with
a skeletal muscle cDNA retroviral library. The ligand,
bacterial-expressed biotinylated globular adiponectin,
was bound to infected cells and then detected with
multiple fluorescent labels. Unusual aspects of the Adi-
poR1 and AdipoR2 molecules include an inverted mem-
brane topology with an intracellular N-terminus, which
is different from other seven-transmembrane spanning
receptors, and a small extracellular C-terminal domain of
approximately 25 amino acids [47]. Another seven-trans-
membrane spanning receptor, the follicle-stimulating
hormone receptor, binds its glycoprotein hormone ligand,
follicle-stimulating hormone, through two 330 residue
extracellular domains [48]. Each of these domains is
almost the size of the entire AdipoR1 (375 amino acids)
or AdipoR2 (311 amino acids). There is precedent forCurrent Opinion in Pharmacology 2005, 5:129–134small receptors to bind to protein hormones, such as the
TNF-a superfamily member ligand TNF-like weak
inducer of apoptosis (TWEAK) and its receptor, the
102 amino acid TWEAK-R [49]. No confirmation of
adiponectin binding to AdipoR1 and AdipoR2 has been
reported; however, there might be other molecules that
are capable of binding to adiponectin.
We used expression cloning on immobilized eukaryotic-
produced adiponectin of BaF3 cells that were transduced
with a retroviral cDNA expression library derived from
undifferentiated C2C12 myocytes. This identified the
glycosylphosphatidylinositol-linked cell-surface molecule
T-cadherin (‘truncated’; also known as H-cadherin and
CDH13) to be a receptor for the hexameric and HMW
forms of eukaryotic-produced adiponectin [50]. Neither
the trimeric globular nor the bacterial-produced adipo-
nectin bound to T-cadherin, suggesting that there might
be another signaling receptor that is as yet unidentified.
T-cadherin is expressed in the intima of the vascular
endothelium as well as in heart, muscle and the nervous
system [51,52] at sites that position it to interact with
adiponectin. Interestingly, T-cadherin is upregulated in
models of intimal damage and neointimal formation,
suggesting a role in controlling cellular proliferation
[53], reminiscent of the findings in adiponectin-knockout
animals.
How might T-cadherin and adiponectin function in car-
diovascular physiology and pathology? First, T-cadherin
might act as a storage depot for adiponectin. As the two
molecules are present in the same tissue compartments,
such an activity might regulate the levels of adiponectin
in the serum, maintaining high levels within the luminal
side of the vasculature, leading to increased adiponectin
activity. An alternative role of T-cadherin might be to
sequester adiponectin. As T-cadherin preferentially
binds to the hexamer and HMW forms of adiponectin,
such binding might reduce the circulating levels of these
isoforms. Over-expression of T-cadherin might then lead
to progressive hyperglycemia and worsening athero-
sclerosis, whereas deletion of T-cadherin might lead to
increased insulin sensitivity by promoting increased adi-
ponectin serum concentration. A third possibility is that
T-cadherin acts as a co-receptor to present adiponectin to
a signaling receptor, possibly in conjunction with a reduc-
tion or cleavage event to generate trimeric or globular
domain adiponectin from hexameric and HMW forms,
or by itself acting as a receptor to signal directly to
downstream pathways. In this case, overexpression of
T-cadherin might lead to increased insulin sensitivity
and endothelial protection, whereas a reduction in the
levels of T-cadherin might lead to diabetes and vascular
disease. Although there is a dearth of information con-
cerning the in vivo activity of T-cadherin, expression of
T-cadherin is increased in the non-atherogenic internal
mammary artery compared with the atherogenic-pronewww.sciencedirect.com
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from damage through association with adiponectin.
Conclusions
Adiponectin, a recently described adipokine, is involved
in the control of metabolism and the regulation of the
cardiovascular endothelium, in which it might play a
central role in the progression of cardiovascular disease.
Thus, it is increasingly recognized as a biomarker for
cardiovascular disease and a possible therapeutic target.
However, the mechanisms by which adiponectin trans-
mits biological signals are not fully understood and will be
the focus of further investigation. Future research will
clarify the role of several proposed adiponectin receptors
and could possibly generate novel therapeutic targets for
cardiovascular disease.
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